Cytodyn Inc. (CYDY) — SEC Filings
Cytodyn Inc. (CYDY) — 33 SEC filings. Latest: 424B3 (Apr 8, 2026). Includes 13 8-K, 7 10-Q, 2 424B3.
View Cytodyn Inc. on SEC EDGAR
Overview
Cytodyn Inc. (CYDY) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 424B3 filed on Apr 8, 2026: CytoDyn Inc. filed a 424B3 prospectus on April 8, 2026, related to its registration statement for securities. The filing details the company's business and financial information as required for public offerings. CytoDyn Inc. is a pharmaceutical company based in Vancouver, WA.
Sentiment Summary
Across 33 filings, the sentiment breakdown is: 3 bearish, 30 neutral. The dominant filing sentiment for Cytodyn Inc. is neutral.
Filing Type Overview
Cytodyn Inc. (CYDY) has filed 1 4, 2 424B3, 7 10-Q, 13 8-K, 2 DEFA14A, 2 DEF 14A, 2 10-K, 1 10-K/A, 2 S-1, 1 SC 13G/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (33)
Risk Profile
Risk Assessment: Of CYDY's 29 recent filings, 3 were flagged as high-risk, 19 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$5.54M |
| EPS | -$0.00 |
| Cash Position | $9.33M |
| Total Assets | $13.48M |
| Total Debt | $112.99M |
Key Executives
- Jacob Lalezari
- Tyler Blok
- Tanya D. Urbach
- David F. Welch
Industry Context
CytoDyn operates in the highly competitive biotechnology sector, focusing on the development of novel antibody-based therapies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on clinical trial outcomes and market adoption of new treatments for unmet medical needs.
Top Tags
10-Q (6) · corporate-governance (5) · financials (4) · regulatory-filing (4) · SEC Filing (4) · proxy-statement (3) · sec-filing (3) · auditor-change (3) · prospectus (2) · pharmaceutical (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| File Number | 333-282000 | Associated with the registration statement for the prospectus |
| Film Number | 26849007 | SEC processing number for the filing |
| 10-Q Document Size | 1989560 | Size of the main 10-Q filing in bytes. |
| Complete Submission Text File Size | 7809994 | Total size of the complete submission text file in bytes. |
| SEC File Number | 000-49908 | Identifies the company's filing history with the SEC. |
| I.R.S. Employer Identification No. | 83-1887078 | Tax identification number for the company. |
| Net Loss | $5.54M | for the three months ended August 31, 2025, compared to $19.23M net income in 2024 |
| Cash and Cash Equivalents | $9.33M | as of August 31, 2025, down from $11.90M on May 31, 2025 |
| Accumulated Deficit | $893.33M | as of August 31, 2025, indicating significant historical losses |
| Research and Development Expenses | $3.23M | for the three months ended August 31, 2025, compared to a gain of $24.05M in 2024 |
| Total Liabilities | $112.99M | as of August 31, 2025, remaining high |
| Common Shares Outstanding | 1,259,753 thousand | as of September 30, 2025 |
| Decrease in Cash and Cash Equivalents | 22.4% | from May 31, 2025, to August 31, 2025 |
| Decrease in Total Current Assets | 25.4% | from May 31, 2025, to August 31, 2025 |
| Current Authorized Shares | 1,750,000,000 | Baseline for common stock before proposed increase |
Forward-Looking Statements
- {"claim":"David F. Welch will continue to hold a significant, but potentially fluctuating, stake in CytoDyn Inc. over the next year.","entity":"David F. Welch","targetDate":"2025-02-12","confidence":"medium"}
- {"claim":"CytoDyn Inc.'s stock price may experience minor volatility if further changes in David F. Welch's ownership are reported.","entity":"CytoDyn Inc.","targetDate":"2024-08-12","confidence":"low"}
Frequently Asked Questions
What are the latest SEC filings for Cytodyn Inc. (CYDY)?
Cytodyn Inc. has 33 recent SEC filings from Jan 2024 to Apr 2026, including 13 8-K, 7 10-Q, 2 424B3. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CYDY filings?
Across 33 filings, the sentiment breakdown is: 3 bearish, 30 neutral. The dominant sentiment is neutral.
Where can I find Cytodyn Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cytodyn Inc. (CYDY) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cytodyn Inc.?
Key financial highlights from Cytodyn Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CYDY?
The investment thesis for CYDY includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cytodyn Inc.?
Key executives identified across Cytodyn Inc.'s filings include Jacob Lalezari, Tyler Blok, Tanya D. Urbach, David F. Welch.
What are the main risk factors for Cytodyn Inc. stock?
Of CYDY's 29 assessed filings, 3 were flagged high-risk, 19 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Cytodyn Inc.?
Recent forward-looking statements from Cytodyn Inc. include guidance on {"claim":"David F. Welch will continue to hold a significant, but potentially fluctuating, stake in CytoDyn Inc. over th and 1 other predictions.